ArticleClinical oral investigations2026
Calcium silicate cement with phosphate-based glass for enhanced osteogenic activity and mechanical strength.
Article in Clinical oral investigations, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesTo investigate the effects of incorporating a phosphate-based glass (PBG) into Endocem MTA, a calcium silicate cement (CSC) material, on its physicochemical, mechanical, and biological properties. MATERIALS AND
methodsPhysicochemical and mechanical properties, including setting time, compressive strength, X-ray diffraction (XRD), pH, and calcium and phosphorus ions release, were evaluated. Biological responses were assessed using pre-osteoblastic cells, including cell proliferation, osteogenic gene expression, alkaline phosphatase (ALP) staining, and biomineralization (Alizarin Red S staining) for Endocem MTA with 1 or 3 wt% PBG.
resultsIncorporation of 3 wt% PBG into CSC (CSP3) resulted in an approximately 15% longer setting time (p < 0.01) and 51.3% less compressive strength after immersion in deionized water (p < 0.001). Brushite was detected in the CSP3 group due to the reaction between calcium and phosphate ions. All three groups maintained an alkaline environment. The CSP3 had significantly higher phosphate ion release (p < 0.001) but 1 wt% PBG into CSC (CSP1) had better cytocompatibility and enhanced osteogenic differentiation, as evidenced by the upregulation of osteogenic markers, increased ALP activity, and greater calcium deposition compared with the CSC group (p < 0.01).
conclusionIncorporation of 1 wt% PBG into a CSC product enhanced osteogenic activity without significantly compromising its physicochemical and mechanical properties. CLINICAL RELEVANCE: The addition of 1 wt% PBG into Endocem MTA may improve osteogenic potential without compromising handling or mechanical performance, supporting its clinical application in endodontic treatments.
Indexed as
Identifiers
42018191What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.